Home › Compare › NSFMF vs ABBV
NSFMF yields 3.52% · ABBV yields 3.06%● Live data
📍 NSFMF pulled ahead of the other in Year 6
Combined, NSFMF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NSFMF + ABBV for your $10,000?
Nisshin Seifun Group Inc. engages in the flour milling, processed foods, health foods, biotechnology, pet foods, engineering, and mesh cloth businesses in Japan and internationally. The company manufactures and sells wheat flour, bran, ready-made, and other food-related items; pasta, pasta sauces, premixes, flour for consumer use, heat-and-serve products, dried noodles, and chilled and frozen food products under the NISSHIN, MA?MA, AO-NO-DOKUTSU, and DE CECCO brands; deli foods under the INITIO brand; and health foods, active pharmaceutical ingredients, and pharmaceutical products. It also manufactures and sells pet food for dogs and cats under the JP Style brand; designs and manages manufacturing and processing facilities for grains, food materials, and chemicals; and sells powder processing related equipment. In addition, the company manufactures and sells yeast and other food ingredients, ingredients for diagnostic drugs, and drugs for research; materials for screen-printing, mesh products for industrial use, electronic components, and plastic molding; and deli dishes. Nisshin Seifun Group Inc. was founded in 1900 and is headquartered in Tokyo, Japan.
Full NSFMF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.